肝癌的靶向和免疫治疗

Targeted and immune-based therapies for hepatocellular carcinoma

摘要:

肝癌已成为最常见、最致命的恶性肿瘤之一。近年来，基于靶向性和免疫性药物的第三阶段试验取得了较好结果，更多针对特定肿瘤代谢通路和免疫检查点的药物正在临床研发中，一些药物已经被证明可以改善肝癌患者的预后。肝癌患者的治疗方案正在迅速改变。本文对肝癌患者靶向治疗和免疫治疗药物的机制、副反应、疗效及正在进行的研究作一阐述。

Abstract:

Hepatocellular carcinoma（HCC） has become one of the most common and deadly malignancies. In recent years，the third phase of drugs based on target and immunity has obtained better results，more drugs focusing on specific tumor metabolic pathways and immune checkpoints are under clinical development，and some drugs have been identified that can improve the prognosis of liver cancer patients. Treatments of HCC changes rapidly. This article reviewed the mechanism，side effects，efficacy and ongoing research of targeted therapy and immunotherapy drugs for HCC.